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Background. Renal failure induced by radiographic con-
trast agents is a known complication of coronary angiog-
raphy, especially among patients with chronic renal failure.
Recently, treatment with N-acetylcysteine (NAC) has been
shown to have a protective effect but the mechanisms are
unknown. We examined the hypothesis that NAC protected
against contrast-induced renal impairment through effects on
nitric oxide metabolism and oxidative stress.
Methods. Patients with a serum creatinine concentration
above 106 lmol/L undergoing coronary angiography were ran-
domly assigned to receive either NAC 1 g (N = 24) or placebo
(N = 29) twice daily 24 hours before and after angiography with
0.45% saline hydration in a double-blind study. Creatinine clear-
ance was calculated and urinary nitric oxide and F2-isoprostane
excretion were measured at baseline, 24 and 96 hours after
angiography.
Results. Treatment with NAC significantly improved the ef-
fect of contrast media on creatinine clearance, and maximal
beneficial effect was observed 24 hours after angiography. Cre-
atinine clearance (mL/min) was 59.5 ± 4.4, 64.7 ± 5.8, and
58.7 + 3.9 at baseline, 24, and 96 hours after angiography in the
NAC group, respectively, and 65.2 ± 3.2, 51.5 ± 3.7, and 53.6 ±
3.9 in the placebo group, respectively (P < 0.0001). NAC treat-
ment prevented the reduction in urinary nitric oxide after an-
giography. The urinary nitric oxide/creatinine ratio (lmol/mg)
was 0.0058 ± 0.0004, 0.0057 ± 0.0004, and 0.0052 ± 0.0004 at
baseline, 24, and 96 hours after angiography in NAC group, re-
spectively, and 0.0057 ± 0.0007, 0.0031 ± 0.0005, and 0.0039 ±
0.0005 in the placebo group, respectively (P = 0.013). NAC had
no significant effect on urinary F2-isoprostanes.
Conclusion. NAC treatment has renoprotective effect in
patients with mild chronic renal failure undergoing coronary
angiography that may be mediated in part by an increase in
nitric oxide production.
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Acute renal failure induced by radiographic contrast
agents is a known complication of coronary angiography.
Contrast material is responsible for 12% to 14% of acute
renal failure in hospital [1, 2]. The incidence of contrast
material induced deterioration in renal function is higher
in patients with chronic renal failure, especially those with
diabetic nephropathy [1, 2].
Renal vasoconstriction and medullary hypoxia, medi-
ated by a decrease in nitric oxide production or bioavail-
ability and an increase in oxidative stress, are suggested
mechanisms underlying the pathogenesis of contrast
media-induced nephrotoxicity [3–8]. Since chronic renal
failure is associated with decreased nitric oxide produc-
tion and increased oxidative stress [9–13], patients with
chronic renal failure are more susceptible to contrast
media–induced nephrotoxicity.
Intravenous hydration with saline 0.45% before and
after angiography and the use of nonionic, low os-
molar iodine have been shown to be renoprotective
[3, 14, 15] and are now standard of care in patients
with chronic renal failure undergoing angiographic stud-
ies. Recent studies have shown that treatment with
N-acetylcysteine (NAC), a thiol-containing antioxidant,
in combination with saline hydration and a nonionic, low
osmolar contrast agent has a protective effect against
contrast-induced nephrotoxicity in patients with chronic
renal failure undergoing coronary angiography and com-
puterized tomography studies [16–20]. Animal stud-
ies have suggested that the protective effect of NAC
may be related to its antioxidant properties or inter-
action with nitric oxide metabolism. The potential role
of these mechanisms, however, has not been tested in
humans.
Accordingly, the aim of our study was to evaluate the
effects of NAC treatment on renal function and to de-
termine the contributions of alterations in nitric oxide
metabolism and oxidative stress to the effects of NAC
in patients with mild to moderate chronic renal failure
undergoing coronary angiography.
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METHODS
Patients
The study protocol was approved by the local Ethics
Committee and each patient gave written informed con-
sent. We prospectively enrolled 55 consecutive patients
with a serum creatinine concentration above 106 lmol/L
who were candidates for elective coronary angiography.
Serum creatinine was measured at least twice during the
month preceding the angiography, with more than 1-week
interval between the measurements. Patients who had
less than 45 lmol/L difference were included in our study.
Patients with acute renal failure, acute myocardial infarc-
tion, noncompensated congestive heart failure, hemody-
namic instability, and known sensitivity to contrast media
were excluded.
Study protocol
Patients were randomly assigned to receive either NAC
[Mucomyst 20% solution (Bristol-Meyers, New York,
NY, USA)] (treatment group) diluted in regular Coca-
Cola (30 mL) or Coca-Cola alone (placebo group). NAC
1 g was administered orally twice daily 24 hours be-
fore and 24 hours after coronary angiography. Patients in
the placebo group received Coca-Cola only at the same
schedule. Both groups were treated with intravenous
0.45% saline hydration at a rate of 1 mL/kg/hour for
12 hours before and 12 hours after coronary angiography.
Patients and the physicians were blinded to the treatment
assignment. Coronary angiography was performed using
nonionic, low osmolar iodine (Ultravist-370) (Schering,
Berlin, Germany).
All patients were hospitalized 1 day before and at least
24 hours following angiography. Blood samples for urea
and serum creatinine were drawn on admission, 24 hours
after coronary angiography, and after 96 hours when pa-
tients returned to a follow-up visit. Urine was collected
for 24 hours before angiography, during the first 24 hours
following angiography, and 96 hours after angiography.
Laboratory analysis
Urinary creatinine was measured and creatinine clear-
ance was calculated. Two 10 mL aliquots from each
urine collection were separated and stored at −70◦C
until analyzed for nitric oxide metabolites and urinary
isoprostanes.
Measurement of urinary nitric oxide metabolites
Urinary metabolites of nitric oxide (NOx) (NO2 +
NO3) were measured in the urine collections of the
first 40 patients. Nitrates were enzymatically converted
to nitrites by nitrate reductase (R&D Systems, Inc.,
Minneapolis, MN, USA). Nitrites were then detected by
a colorimeteric method based on the Griess reaction [22].
The precision of the assay is ±5%. Urinary NOx (lmol) is
expressed as total NOx excretion in 24 hours and per mg
of urinary creatinine as NOx/creatinine ratio (lmol/mg).
Based on pharmacokinetic of NAC, an oral bioavail-
ability of 10% and renal clearance of 30% [23, 24], the
estimated urinary NAC concentration after an oral dose
of 2 g is at the range of 0.01 to 0.1 mg/mL. To test whether
acetylcysteine may interfere with the nitrite reductase as-
say, we repeated the assay using escalating concentrations
of NAC in the range of 0.0001 to 1 mg/dL. NAC did not
interfere with the nitrate reductase assay.
Oxidative stress
Oxidative stress was assessed by measurement of uri-
nary isoprostanes, which are secondary end products of
lipid peroxidation and are known to be an accurate and
sensitive marker of renal oxidative stress in vivo [25].
Samples from the 24-hour urine collections of the first
40 patients were used to measure these compounds by
mass spectrometry as previously described [26], and the
results were expressed as pg/mg of urinary creatinine.
The precision of the assay for F2-isoprostane is ±7%.
The interday variability in F2-isoprostane excretion
in the same individual is approximately 8%. Urinary cre-
atinine was quantified by the sodium picrate method with
an Autoanalyzer II (Technicon, Tarrytown, NY, USA).
Investigators involved in the measurement of urinary
NOx and isoprostanes were blinded to the patients’
treatment.
Statistical analysis
Continuous baseline variables were compared be-
tween the treatment groups by an unpaired t test and by
a paired t test within each group. Categorical parameters
were compared by a chi-square test. The effect of NAC
treatment on serum creatinine, creatinine clearance, uri-
nary NOx, and urinary isoprostanes at baseline and 48 and
96 hours following angiography was compared between
the groups by a general linear model repeated-measures
analysis of variance (ANOVA). The statistical software
SPSS (version 10.0, SPSS, Inc., Chicago, IL, USA) was
used for all analyses. All tests were two tailed. P values
below 0.05 were considered significant. Data are ex-
pressed as mean ± SEM.
RESULTS
Fifty-five patients were enrolled and randomized. Data
from six patients (four NAC and two controls) were
excluded from final analysis. One patient developed
acute myocardial infarction after coronary angiography,
one patient chose to withdraw from the study after an-
giography, and four patients did not arrive at the follow-
up visit. Data from the remaining 49 patients were used in
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Table 1. Baseline clinical characteristics
NAC Placebo
(N = 24) (N = 25) P value
Age years 68 ± 1.9 66 ± 1.9 0.62
Gender M/F 21/3 23/2 0.6
Diabetes mellitus 14 (58%) 12 (48%) 0.47
Congestive heart failure 12 (50%) 11 (44%) 0.88
Peripheral vascular disease 9 (38%) 12 (48%) 0.46
History of stroke 1 (4%) 1 (4%) 0.8
Body mass index kg/m2 27 ± 0.7 26.8 ± 0.6 0.61
Mean arterial pressure 100.8 ± 2.6 104 ± 4.04 0.4
mm Hg
Drug therapy
Diuretics 11 (46%) 16 (64%) 0.2
Calcium-channel blockers 14 (58%) 10 (40%) 0.2
ACE inhibitors or Ang II 16 (67%) 17 (68%) 0.91
receptor blockers
Nitrates 11 (46%) 10 (40%) 0.68
Carvedilol 1 (4%) 1 (4%) 0.98
Beta blockers 19 (79%) 16 (64%) 0.28
Aspirin 23 (96%) 21 (84%) 0.325
Coronary angiography
characteristics
Percutaneous transluminal 11 (46%) 9 (36%) 0.49
coronary angioplasty
Contrast media volume mL 142 ± 25.3 138 ± 33.7 0.76
Abbreviations are: ACE, angiotensin-converting enzyme; NAC, N-
acetylcysteine; Ang II, angiotensin II.
Data are mean ± SEM.
Mean arterial pressure = diastolic blood pressure + 1/3 pulse pressure.
the final analysis. Twenty-four patients were treated with
NAC and 29 patients received placebo. For technical rea-
sons, urinary NOx and isoprostanes were measured only
in 40 patients (18 NAC 18 and 22 control). There were no
significant differences in the baseline clinical and labora-
tory characteristics between this group and the remaining
nine patients.
Baseline clinical and biochemical characteristics of the
patients are summarized in Tables 1 and 2. There were
no statistically significant differences between treatment
group and the placebo group in any of the baseline charac-
teristics. Mean contrast media volume and the percentage
of patients who underwent percutaneous coronary angio-
plasty were similar in both groups (Table 1). Two patients
had an increase in their serum creatinine by more than
25% following angiography, both were from the placebo
group (one patient after 24 hours and one after 96 hours).
None of the patients needed renal replacement therapy
during the follow-up period and there were no side effects
related to NAC treatment.
Creatinine clearance at baseline, 24, and 96 hours after
angiography are shown in Table 2. Treatment with NAC
significantly influenced the effects of angiography on cre-
atinine clearance response to contrast media (P < 0.0001
repeated-measures ANOVA). Twenty-four hours after
angiography, creatinine clearance in the control group
patients decreased significantly (from 65.3 ± 3.2 mL/min
before angiography to 51.5 ± 3.7 mL/min after angiogra-
phy P < 0.0001, paired t test), while in the NAC-treated
Table 2. Biochemical characteristics at baseline, 24, and 96 hours
after coronary angiography in patients receiving N-acetylcysteine
(NAC) or placebo
Baseline 24 hours 96 hours
Serum creatinine
lmol/La
NAC (N = 24) 135.25 ± 6.19 133.5 ± 7.07 143.2 ± 6.19b
Control (N = 25) 131.7 ± 6.19 142.3 ± 6.19b 143.2 ± 7.02b
Blood urea nitrogena
NAC (N = 24) 20.1 ± 4.5 16.6 ± 2.9b,c 18.5 ± 4.8
Control (N = 25) 17.9 ± 4.3 20.5 ± 3.6b 19.6 ± 5.6b
Creatinine clearance
mL/mina
NAC (N = 24) 59.46 ± 4.4 64.76 ± 5.8c 58.73 ± 3.9
Control (N = 25) 65.28 ± 3.2 51.50 ± 3.7b 53.36 ± 3.9b
Urinary NOx
lmol/24 hoursa
NAC (N = 18) 562.1 ± 119 497 ± 128 489.3 ± 115
Control (N = 22) 687.1 ± 111 295 ± 69b 478.3 ± 152
Urinary NOx/creatinine
ratio lmol/mga
NAC (N = 18) 0.0058 ± 0.0004 0.0057 ± 0.0004c 0.0052 ± 0.0004
Control (N = 22) 0.0057 ± 0.0007 0.0031 ± 0.0005b 0.0039 ± 0.0005b
Urinary F2-isoprostanes/
creatinine ratios (ng/mg)
NAC (N = 18) 0.82 ± 0.08 1.06 ± 0.18 0.96 ± 0.17
Control (N = 22) 0.94 ± 0.09 1.16 ± 0.23 0.97 ± 0.17
Data are mean ± SEM.
aP < 0.01 repeated-measures analysis of variance (ANOVA) comparing the effect
of NAC treatment.
bP < 0.005 paired t test compared to baseline.
cP < 0.05 unpaired t test comparing NAC and control groups.
patients creatinine clearance increased (from 59.5 ±
4.4 mL/min before angiography to 64.8 ± 5.8 mL/min af-
ter angiography P = 0.13, paired t test). Ninety-six hours
after angiography, creatinine clearance was still signif-
icantly lower than baseline in the placebo group (P =
0.001) (Table 2). In the patients treated with NAC, creati-
nine clearance decreased back to baseline although none
of these changes were statistically significant (P = 0.17).
Changes in creatinine clearance from baseline, 24, and
96 hours after angiography are shown in Figure 1. Serum
creatinine and blood urea nitrogen changes were simi-
lar to those of creatinine clearance and were statistically
significant (P = 0.006 and P < 0.001 repeated-measures
ANOVA for serum creatinine and blood urea nitrogen,
respectively) (Table 2).
Baseline urinary NOx and NOx/creatinine ratios were
similar between the NAC-treated and placebo groups
(Table 2). Treatment with NAC significantly influenced
the effects of angiography on both urinary NOx and NOx/
creatinine ratio responses to contrast media (P = 0.013
repeated-measures ANOVA) (Table 2). The urinary
NOx/creatinine ratio, a measure of nitric oxide produc-
tion, decreased significantly 24 hours after angiography
in the placebo group (from 0.0057 ± 0.0007 umol/mg at
baseline to 0.0031 ± 0.0005 umol/mg at 24 hours after
angiography, P = 0.001, paired t test), and remained sig-
nificantly lower (0.0039 ± 0.0005 umol/mg 96 hours after
angiography, P = 0.004, paired t test). However, in the
patients treated with NAC, the urinary NOx/creatinine
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Fig. 1. Changes from baseline in creatinine clearance 24 and 96 hours
after coronary angiography in patients receiving N-acetylcysteine
(NAC) (N = 24) and placebo (N = 25). ∗P value for the comparison
between the groups.
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Fig. 2. Changes in urinary NOx/creatinine ratio 24 and 96 hours af-
ter coronary angiography in patients receiving N-acetylcysteine (NAC)
(N = 18) and placebo (N = 22). ∗P value for the comparison between
the groups.
ratio did not change significantly (P = 0.82 and P = 0.2,
24 hours and 96 hours after angiography, respectively,
paired t test). Changes in urinary NOx/creatinine ra-
tio from baseline 24 and 96 hours after angiography
are shown in Figure 2. There was no correlation be-
tween the changes in creatinine clearance and urinary
NOx/creatinine ratio (R2 = 0.04).
Urinary isoprostane/creatinine ratios at baseline were
0.82 ± 0.08 ng/mg and 0.94 ± 0.09 ng/mg in the NAC-
treated and placebo groups, respectively, P = 0.34.
Administration of radiocontrast increased urinary iso-
prostane excretion by approximately 28% in both groups
but this was not significant in either groups (P = 0.165 and
P = 0.3 in NAC-treated and placebo groups, respectively)
(Table 2). There was no correlation between changes
in urinary isoprostane/creatinine ratios and changes in
NOx/creatinine ratios (R2 = 0.025).
DISCUSSION
In this study we have shown that treatment with NAC
before and after coronary angiography had a protective
effect against contrast media-induced nephrotoxicity in
patients with mild chronic renal failure. This effect was
seen at both short (24 hours) and relative long term
(96 hours), and was additive to the protective effect of
saline hydration and the usage of a nonionic low osmo-
lar contrast agent. Our results add significant information
to studies of patients with chronic renal failure undergo-
ing computerized tomography [16], and recently, coro-
nary angiography [17–21]. Using creatinine clearance we
were able to detect significant, although subtle, changes
in renal function following angiography even though the
overall rate of clinically significant deterioration in renal
function (increase in baseline serum creatinine>25%)
in our study was low (4%) and none of the patients
needed renal replacement therapy. This rate is lower
than reported by Tepel et al (12%) [16], Diaz-Sandoval,
Kosowsky, and Losordo (28%) [18], and Shyu, Cheng,
and Kuan (14%) [17]. In these studies, however, patients
had a higher baseline serum creatinine (212 lmol/L or
247 lmol/L vs. 133 lmol/L in our study) or the volume
of contrast media was significantly greater (184 mL) than
in our study (140 mL). The rate is also lower than re-
ported by Kay et al [20], although the general trend in
mean creatinine clearance is similar. No beneficial effect
was reported by Durham et al [21], where the mean vol-
ume of contrast media was 81 mL and only two doses of
NAC treatment were given. In a recent study, performed
by Briguori et al [19], patients’ baseline serum creatinine
and volumes of contrast media were similar to our study
and the protective effect of NAC treatment was similar.
Taken together, our results and those of Briguori et al
[19] indicate that in most patients with mild renal failure
NAC treatment does not confer a clinically significant
protective effect over saline hydration alone although
alterations in creatinine clearance are prevented.
Our study is the first study in humans that provides
insight into the possible mechanisms of renoprotection
by NAC. Renal vasoconstriction, possibly mediated by
alterations in nitric oxide, and a direct toxic effect of con-
trast media agents have been implicated in the pathogen-
esis of contrast media–induced nephrotoxicity in studies
performed in both animals and humans [3–8]. Contrast
media agents can cause a direct tubular injury, leading
to the generation of oxygen free radicals [3–5], which
in turn react with nitric oxide to produce peroxynitrite.
Peroxynitrite is a potent oxidant that further decreases
nitric oxide bioavailability [27, 28] and results in more
tissue injury. Patients with chronic renal failure, diabetes
mellitus, and heart failure have impaired nitric oxide
activity, which could account for their susceptibility to de-
velop contrast media nephrotoxicity [7, 29–31]. Baseline
urinary NOx in our patients are comparable to reported
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values by other groups in patients with chronic renal fail-
ure [9, 10]. Angiography resulted in a significant decrease
in urinary NOx in the placebo group, most likely reflect-
ing decreased production. The decrease in urinary NOx
coincided with the decrease in renal function; however,
the lack of correlation between changes in NOx and
changes in creatinine clearance may indicate that the de-
crease in nitric oxide production had a causative role,
rather than being the result of a decrease in renal func-
tion. The decrease in urinary NOx in the placebo group
compared with no decrease in the NAC-treated group
implies that NAC treatment resulted in an increase in ni-
tric oxide production or protected against the contrast
media–induced reduction in nitric oxide production. In
support of the suggestion that nitric oxide production was
increased is the in vitro observation that NAC can induce
endothelial nitric oxide synthase expression [32].
Dietary substances containing nitrates and nitrites and
cigarettes can affect the urinary NOx levels. Although
not on a strict diet, all patients fasted for 12 hours be-
fore angiography and for 6 hours after angiography,
decreasing dietary component in urinary nitrites as has
been shown before [33]. After that, all patients were al-
lowed a light standard meal provided by the hospital,
thus minimizing the confounding effects of dietary ni-
trites. Another source of nitrites is cigarette smoking but
none of the patients smoked during their hospital stay
and the percentage of smokers was the same in both
groups.
In addition to increasing nitric oxide production, NAC
can also potentiate the hemodynamic effects of nitric
oxide by binding to it and forming a more stable sub-
stance, as evident from human studies where NAC treat-
ment significantly enhanced endothelium-dependent
vasodilation [34]. Thus, NAC may act as a renal vasodila-
tor through several mechanisms. The decrease in serum
creatinine and blood urea nitrogen and the increase in
creatinine clearance most likely reflect the increase of
glomerular filtration rate (GFR) caused by NAC renal
vasodilator effect.
NAC is a thiol-containing antioxidant. Animal stud-
ies showed that NAC treatment had a protective effect
in models involving increased oxidative stress such as
reperfusion injury [35–37] and contrast media–induced
nephrotoxicity but no studies have been performed in
humans. We used urinary excretion of isoprostanes, a
reliable measure of oxidative stress, to determine if the
potential antioxidant effects of NAC explained its abil-
ity to protect against contrast-induced impairment of re-
nal function. Neither contrast media exposure nor NAC
treatment had any effect on urinary isoprostanes, indi-
cating that in humans increased oxidative stress may not
play an important role in contrast media nephrotoxicity
and that antioxidant mechanisms are unlikely to explain
the renoprotective effects of NAC.
CONCLUSION
NAC treatment has a short and relative long-term
renoprotective effect in patients with chronic renal
failure undergoing coronary angiography. Part of the
renoprotective effects of NAC may be due to its amelio-
rating effect on the expected contrast-induced reduction
of nitric oxide and postulated antioxidant mechanisms
appear to be less important. Further studies on the ef-
fects of chronic NAC treatment in patients with chronic
renal failure would be of interest.
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